Stocks · Healthcare · Biotechnology
C4 Therapeutics, Inc. CCCC
$2.95 -6.05% Close, Oct 2, 2026 · NASDAQ · Market cap $326.2M
Expensive vs sectorHigh risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -319.0% from -361.0% a year earlier.
- The diluted share count rose 84.1% in a year.
- The stock is 37% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 33%
- Revenue growth, 3-year CAGRBottom 37%
- Revenue growth accelerationTop 10%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 37%
- Gross marginTop 13%
- Operating marginBottom 20%
- Accruals (lower is better)Bottom 40%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 21%
- Free-cash-flow yieldBottom 20%
- EBITDA / enterprise valueBottom 20%
- Sales / enterprise valueBottom 34%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 24%
- 6-month returnBottom 47%
- 1-year return vs S&P 500Top 32%
- Distance from 52-week highBottom 37%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 26%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyBottom 41%
- Upside to consensus price targetTop 12%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 48%
- Maximum drawdown, 3 yearsBottom 16%
- Beta vs S&P 500 (lower is better)Bottom 6%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -12.4% | 2.3% | ↑ |
| Gross margin | 88.8% | 94.9% | ↑ |
| Operating margin | -361.0% | -319.0% | ↑ |
| FCF margin | -255.8% | -243.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 2.3% | -12.4% | ↑ | Bottom 33% |
| Gross margin | 94.9% | 88.8% | ↑ | Top 13% |
| Operating margin | -319.0% | -361.0% | ↑ | Bottom 20% |
| Net margin | -289.4% | -325.9% | ↑ | — |
| Free-cash-flow margin | -243.7% | -255.8% | ↑ | — |
| Return on invested capital | -35.2% | — | Bottom 37% | |
| Revenue growth, 3-year CAGR | 5.0% | — | Bottom 37% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 40.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -40.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -49.15%
- Shareholder yield
- -49.15%
- Share count change, 1 year
- +84.1%
- Share count change, 3-year CAGR
- +38.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +18.5%
- Average 2-day reaction, last 8
- +2.6%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $11.33
- Target vs current price
- +284.1%
- Analysts with a rating
- 14
- Share rating Buy or Strong Buy
- 71%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | +20.5% | +6.9% | +17.7% | -1.9% | — |
| May 12, 2026 | +20.2% | +0.0% | +1.6% | +12.9% | +14.8% |
| Feb 26, 2026 | +41.9% | +0.4% | +11.6% | -2.9% | +27.1% |
| Nov 6, 2025 | -8.5% | +0.4% | +4.6% | +9.3% | -15.2% |
| Aug 7, 2025 | +2.6% | +31.6% | +18.9% | +36.2% | +25.5% |
| May 6, 2025 | +22.9% | -13.0% | -2.5% | -8.6% | +26.5% |
| Feb 27, 2025 | -8.9% | -1.9% | -8.3% | -30.2% | -48.3% |
| Oct 31, 2024 | +7.9% | -3.6% | +8.0% | -17.7% | -35.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.18 | -$0.23 | +20.5% | $6.6M |
| May 12, 2026 | -$0.20 | -$0.25 | +20.2% | $6.2M |
| Feb 26, 2026 | -$0.18 | -$0.31 | +41.9% | $11.0M |
| Nov 6, 2025 | -$0.44 | -$0.41 | -8.5% | $11.2M |
| Aug 7, 2025 | -$0.37 | -$0.38 | +2.6% | $6.5M |
| May 6, 2025 | -$0.37 | -$0.48 | +22.9% | $7.2M |
| Feb 27, 2025 | -$0.49 | -$0.45 | -8.9% | $5.2M |
| Oct 31, 2024 | -$0.35 | -$0.38 | +7.9% | $15.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 8.69× | — | — | Bottom 34% |
| Free-cash-flow yield | -26.18% | — | — | Bottom 20% |
| Earnings yield | -33.90% | — | — | Bottom 21% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.5%
- 200-day average slope (20 days)
- +2.5%
- Distance from 50-day average
- -18.7%
- Distance from 200-day average
- -5.3%
- RSI (14)
- 33.8
- Relative volume
- 1.64×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 56.7%
- Volatility vs own 5-year history
- 7th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.35
- Correlation with S&P 500
- 0.40
- Current drawdown from 1-year high
- -36.8%
- Maximum drawdown, 3 years
- -90.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 23, 2021 | Apr 16, 2025 | -97.8% | 894 days | Not yet recovered |
| Feb 10, 2021 | Apr 20, 2021 | -34.6% | 47 days | 97 days (Sep 7, 2021) |
| Nov 27, 2020 | Dec 11, 2020 | -19.1% | 10 days | 8 days (Dec 23, 2020) |
| Oct 6, 2020 | Oct 9, 2020 | -15.4% | 3 days | 7 days (Oct 20, 2020) |
| Dec 23, 2020 | Jan 4, 2021 | -13.7% | 6 days | 5 days (Jan 11, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $326.2M
- EPS, diluted (TTM)
- -$1.00
- Revenue (TTM)
- $35.0M
- 52-week range
- $1.69 – $5.17
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Gross profit | $45.8M | $31.1M | $13.0M | $35.6M | $28.0M |
| Operating income | -$82.1M | -$129.5M | -$139.0M | -$119.6M | -$104.5M |
| Net income | -$83.9M | -$128.2M | -$132.5M | -$105.3M | -$105.0M |
| EPS (diluted) | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.4M | $5.2M | $7.2M | $6.5M | $11.2M | $11.0M | $6.2M | $6.6M |
| Net income | -$24.7M | -$34.6M | -$26.3M | -$26.0M | -$32.2M | -$20.5M | -$25.1M | -$23.6M |
| EPS (diluted) | -$0.35 | -$0.49 | -$0.37 | -$0.37 | -$0.44 | -$0.18 | -$0.20 | -$0.18 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$87.0M | -$105.9M | -$106.8M | -$65.2M | -$98.7M |
| Capital expenditure | -$1.3M | -$5.5M | -$1.7M | -$180,000 | -$607,000 |
| Free cash flow | -$88.2M | -$111.4M | -$108.5M | -$65.3M | -$99.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $169.5M | $777,000 | $57.6M | $44.2M | $126.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $253.7M
- Total assets
- $359.4M
- Total liabilities
- $112.1M
- Total debt
- $56.9M
- Net debt
- -$21.8M
- Shareholders’ equity
- $247.3M
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 40,189,287
- Days to cover
- 22.68
- Change vs previous report
- +7.4%
FINRA short interest, settlement date Sep 15, 2026.